Login to Your Account



Deal Brings Investors $100M Up Front

Shire's $325M FerroKin Buy Validates Iron Chelator Drug

By Marie Powers
Staff Writer

Friday, March 16, 2012
Ireland's Shire plc bulked up its hematology business by scooping up small biotech FerroKin BioSciences Inc. for $100 million in up-front cash, plus potential milestone payments of up to $225 million based on achieving clinical development, regulatory and net sales targets.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription